Brain, Vol. 123, No. 7, 1495-1504,
July 2000
© 2000 Oxford University Press
The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation
1 Service de Neurologie and Laboratoire Louis Ranvier, 2 Service d'explorations fonctionnelles du système nerveux and 3 Département d'Epidémiologie, INSERM U 292, Hôpital de Bicêtre, Le Kremlin-Bicêtre, 4 Centre Hépato-Biliaire, Hôpital Paul-Brousse, Villejuif, Assistance Publique Hôpitaux de Paris, Université de Paris Sud, France, 5 Third Department of Internal Medicine, Miyazaki Medical College, Miyazaki, Japan and 6 Centro de Estudos de Paramyloidosis, Santo Antonio, Porto, Portugal
Correspondence to:
Dr David Adams, Service de Neurologie, Hôpital de Bicêtre, Le Kremlin-Bicêtre, 94275 Cedex, France
Familial amyloid polyneuropathy (FAP) associated with mutations of the transthyretin (TTR) gene is the most common type of FAP, a devastating disease causing death within 10 years after the first symptoms. Because most of the amyloidogenic mutated TTR is secreted by the liver, transplantation is widely used to treat these patients, but long-term quantitative evaluation of the effects of liver transplantation on the progression of the neuropathy are not available. We have treated 45 patients with symptomatic TTR-FAP, including 43 with the Met30 TTR gene mutation, and report on the results of periodic evaluation of markers of neuropathy in 25 of them, who have been followed for more than 2 years after liver transplantation (mean follow-up 4 years). The overall survival rates at 1 and 5 years were 82 and 60%, respectively. Urinary incontinence and a low Norris score at liver transplantation were associated with poorer outcome. The motor score stabilized in seven of 11 patients (64%) with mild sensorimotor neuropathy (walking unaided) and in two of the eight patients (25%) with severe sensorimotor deficit (walking with aid) at liver transplantation. In five other patients, deterioration of motor deficit occurred only within the first year after liver transplantation, but was progressive after this interval in two patients. None of the six patients with pure sensory neuropathy developed motor loss and superficial sensory loss remained unchanged. Two years after liver transplantation, the rate of myelinated axon loss in nerve biopsy specimens was markedly lower in seven transplanted patients (0.9/mm2 of endoneurial area/month) than in non-transplanted patients (70/mm2 of endoneurial area/month). Symptoms of dysautonomia and quantitated cardiocirculatory autonomic tests remained unchanged. In all patients, serum mutated TTR decreased to 2.5% of pre-liver transplantation values and remained at this level during follow-up. We presently recommend liver transplantation in FAP patients at onset of first symptoms and exclusion of those with a Norris score below 55 and/or with urinary incontinence.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. Plante-Bordeneuve, A. Ferreira, T. Lalu, C. Zaros, C. Lacroix, D. Adams, and G. Said Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP) Neurology, August 14, 2007; 69(7): 693 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Douglass, K Suvarna, M M Reilly, P N Hawkins, and M Hadjivassiliou A novel amyloidogenic transthyretin variant, Gly53Ala, associated with intermittent headaches and ataxia J. Neurol. Neurosurg. Psychiatry, February 1, 2007; 78(2): 193 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Shah, Y. Inoue, and M. R. Mehra Amyloidosis and the heart: a comprehensive review. Arch Intern Med, September 25, 2006; 166(17): 1805 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Blevins, R. Macaulay, S. Harder, D. Fladeland, T. Yamashita, M. Yazaki, K. Hamidi Asl, M. D. Benson, and J. R. Donat Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His Neurology, May 27, 2003; 60(10): 1625 - 1630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Buttmann, M Marziniak, K V Toyka, C Sommer, and K Altland "Sporadic" familial amyloidotic polyneuropathy in a German patient with B cell lymphocytic leukaemia J. Neurol. Neurosurg. Psychiatry, July 1, 2002; 73(1): 86 - 87. [Full Text] [PDF]
|
|
|
|
|
|
S.-i. Ikeda, M. Nakazato, Y. Ando, and G. Sobue Familial transthyretin-type amyloid polyneuropathy in Japan: Clinical and genetic heterogeneity Neurology, April 9, 2002; 58(7): 1001 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Delahaye, D. Le Guludec, S. Dinanian, J. Delforge, M. S. Slama, L. Sarda, F. Dolle, H. Mzabi, D. Samuel, D. Adams, et al. Myocardial Muscarinic Receptor Upregulation and Normal Response to Isoproterenol in Denervated Hearts by Familial Amyloid Polyneuropathy Circulation, December 11, 2001; 104(24): 2911 - 2916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Hund, R. P. Linke, F. Willig, and A. Grau Transthyretin-associated neuropathic amyloidosis: Pathogenesis and treatment Neurology, February 27, 2001; 56(4): 431 - 435. [Abstract] [Full Text] [PDF]
|
|